Redx Pharma is a drug discovery and development company formed in 2010. It is focused on improving the characteristics of existing drug classes to create best-in-class new drugs in the areas of cancer, infection and autoimmune disease. The company's work has been endorsed by partnerships with global pharmaceutical companies and the NHS.

Find out more

Latest News

Redx to present Preclinical Data on Novel Bacterial Topoisomerase Inhibitors at ASM Microbe 2016 Conference
17 June 2016

preview image of Redx Poster SU-463, ASM Microbe 2016

Redx Pharma Plc is pleased to announce that it will present data on its novel bacterial topoisomerase inhibitors (NBTIs) at the inaugural annual American Society for Microbiology (ASM) Microbe 2016 conference taking place from 16-20 June in Boston, Massachusetts.

Both the rise of antimicrobial resistance and the current antibiotic innovation gap have highlighted the need for novel antimicrobial agents, particularly for the treatment of Gram-negative bacterial infections.

Read more

We're Hiring

As a fast-growing dynamic business we are continually looking for talented people to join our team.

Work for us

Investor News

24 May 2016

Our unaudited interim results for the six months ended 31 March 2016 are available to download.

Investor Resources

Our Subsidiary Companies

Discovering and developing new therapeutics in the area of infectious disease generating a pipeline of novel antibacterial & antiviral drugs.

View details

Modulating the immune system with novel small molecules to treat a range of diseases with high unmet medical need.

View details

Delivering multiple development candidates across a range of mechanistic approaches in cancer treatment.

View details